ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,335.81
-0.28%
Dow Jones
45,014.04
0.69%
Gold vs US Dollar
2,649.205
-0.05%
Brent Oil
72.425
0.00%
Bitcoin
98,945.78
0.18%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Camurus Ab (0RD1)

  7. Camurus Ab (0RD1) News

Camurus Ab (0RD1)

Camurus Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RD1
DateTimeSourceHeadlineSymbolCompany
17/07/202305:40PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
17/07/202305:36PR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
24/05/202303:25PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
24/05/202303:17PR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
15/12/202122:15PR Newswire (US)Braeburn receives new Complete Response Letter for Brixadi in the USLSE:0RD1Camurus Ab
16/09/202109:38PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
16/09/202109:37PR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
26/06/202116:09PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
26/06/202116:02PR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
15/06/202122:12PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
15/06/202122:05PR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
10/05/202115:22PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
10/05/202115:21PR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
03/05/202106:42PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
03/05/202106:40PR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
26/03/202113:33PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
26/03/202113:32PR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202007:27PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
18/12/202007:26PR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
24/06/202012:38PR Newswire (US)Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...LSE:0RD1Camurus Ab
23/06/202014:39PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
23/06/202014:33PR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
01/06/202021:55PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
01/06/202021:52PR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
14/05/202015:24PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
14/05/202015:22PR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
07/05/202011:18PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
07/05/202011:17PR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
02/04/202006:37PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
02/04/202006:32PR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
 Showing the most relevant articles for your search:LSE:0RD1

Your Recent History

BIT
UB8KNM
Unicredit Bank
BIT
UC6GMH
Unicredit Bank
BIT
UC8YK8
Unicredit Bank
BIT
UI349C
Unicredit Bank
BIT
W2LBG4
UBS
BIT
UC8T37
Unicredit Bank
BIT
UC6BGC
Unicredit Bank
BIT
UC84GR
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved